(Q56897633)

English

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial

scientific article published on 02 August 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22858559%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22858559%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

multicenter clinical trial

1 reference

based on heuristic

inferred from title

phase II clinical trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Igor N. Bondarenko

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22858559%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

author name string

M Reck

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22858559%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

A Luft

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22858559%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

P Serwatowski

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22858559%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

F Barlesi

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22858559%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

R Chacko

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22858559%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

M Sebastian

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22858559%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

H Lu

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22858559%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

J-M Cuillerot

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22858559%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

T J Lynch

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22858559%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

language of work or name

0 references

publication date

2 August 2012

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22858559%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22858559%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

24

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22858559%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22858559%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

75-83

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22858559%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Treatment options for small cell lung cancer - do we have more choice?

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS213

21 January 2018

Twenty-seven years of phase III trials for patients with extensive disease small-cell lung cancer: disappointing results

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS213

21 January 2018

CTLA-4 can function as a negative regulator of T cell activation

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS213

21 January 2018

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS213

21 January 2018

Enhancement of antitumor immunity by CTLA-4 blockade

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS213

21 January 2018

Targeting cytotoxic T-lymphocyte antigen 4 in immunotherapies for melanoma and other cancers

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS213

21 January 2018

Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS213

21 January 2018

Releasing the brake on the immune system: ipilimumab in melanoma and other tumors

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS213

21 January 2018

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS213

21 January 2018

Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS213

21 January 2018

Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS213

21 January 2018

Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS213

21 January 2018

The biologic importance of tumor-infiltrating lymphocytes

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS213

21 January 2018

A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS213

21 January 2018

Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS213

21 January 2018

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS213

21 January 2018

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS213

21 January 2018

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS213

21 January 2018

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS213

21 January 2018

Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS213

21 January 2018

Regulatory T cells in paraneoplastic neurological syndromes

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS213

21 January 2018

Cisplatin augments cytotoxic T-lymphocyte-mediated antitumor immunity in poorly immunogenic murine lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS213

21 January 2018

Immunogenic cancer cell death: a key-lock paradigm

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS213

21 January 2018

Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS213

21 January 2018

Chemotherapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide-specific CTLs

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS213

21 January 2018

Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS213

21 January 2018

Chemoimmunotherapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS213

21 January 2018

Immunological aspects of cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS213

21 January 2018

Synergistic activity of ixabepilone plus other anticancer agents: preclinical and clinical evidence

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS213

21 January 2018

Paclitaxel (175 mg/m2) plus carboplatin (6 AUC) versus paclitaxel (225 mg/m2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): a multicenter randomized trial. Hellenic Cooperative Oncology Group (HeCOG)

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS213

21 January 2018

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS213

21 January 2018

Carboplatin plus paclitaxel in extensive small cell lung cancer: a multicentre phase 2 study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS213

21 January 2018

Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS213

21 January 2018

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS213

21 January 2018

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS213

21 January 2018

THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS213

21 January 2018

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS213

21 January 2018

The Immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS213

21 January 2018

The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS213

21 January 2018

Identifiers

10.1093/ANNONC/MDS213

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22858559%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22858559%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q56897633&oldid=2176528122"